BluePrint Medicines KIT D816V BLU-SM-1101 Evalute the prevalence of the KIT D816V mutation i peripheral blood of patients with evidence of systemic mast cell activation

Clinical Trial Grant

Duke Scholars

Principal Investigator Patricia Lynne Lugar Medicine, Pulmonary, Allergy, and Critical Care Medicine

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Blueprint Medicines Corporation

Start Date

February 9, 2022

End Date

January 9, 2024

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Blueprint Medicines Corporation

Start Date

February 9, 2022

End Date

January 9, 2024